Stellate Ganglion Block to Treat Long COVID 19 Case Series

Completed

• Conditions: Dizziness; Long COVID; Post-COVID-19 Syndrome; Dysautonomia; Anosmia; Muscle Pain; Fatigue Post Viral; Post Acute COVID-19 Syndrome; Brain Fog; Shortness of Breath
• Interventions: Procedure: Stellate Ganglion Block

• Registration Number: NCT05812209
• Lead Sponsor: Metamorphosis LTD

Brief Summary

An assessment of the effectiveness of Stellate Ganglion Block in alleviating symptoms of Long COVID-19.

Detailed Description

We evaluated the treatment results of 41 patients (18 male and 23 female) aged between 18 and 89, who received Stellate Ganglion Block (SGB) with Ultrasound guidance for Long COVID-19 Syndrome. The patients were from the United States and received treatment at our Colorado clinics during the period of September to December 2022.Those who responded to our post-procedure follow-up calls were included in the study population.

Study Timeline

• Study Start: 2022-09-01
• Primary Completion: 2022-12-31
• Study Completion: 2022-12-31
• Status Verified: 2023-04
• Study First Submitted: 2023-04-10
• Study First Submitted QC: 2023-04-10
• Last Update Submitted: 2023-04-10
• Study First Posted: 2023-04-13
• Last Update Posted: 2023-04-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 41

Inclusion Criteria

People who scheduled themselves for a SGB in our clinics in Colorado.

Exclusion Criteria

Stellate Ganglion Block Contraindications

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
SGB Patients for Long COVID 19	Stellate Ganglion Block	Patients who received ultrasound guided Stellate Ganglion block for symptoms of Long COVID in our Colorado clinics.

Primary Outcome Measures

Name	Time	Method
Symptom Response	3 months	Evaluation of the symptoms response to the Stellate Ganglion Block

Trial Locations

Locations (1)

Metamorphosis LTD; 🇺🇸 Cañon City, Colorado, United States